التفاصيل البيبلوغرافية
| العنوان: |
Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections |
| المؤلفون: |
Giustino Parruti, Ennio Polilli, Simona Coladonato, Giorgia Rapacchiale, Francesca Trave, Elena Mazzotta, Martina Bondanese, Francesco Di Masi, Davide Recinelli, Serena Corridoni, Alberto Costantini, Stefano Ianniruberto, Pierluigi Cacciatore, Fabrizio Carinci |
| المصدر: |
Antibiotics, Vol 13, Iss 11, p 1063 (2024) |
| بيانات النشر: |
MDPI AG, 2024. |
| سنة النشر: |
2024 |
| المجموعة: |
LCC:Therapeutics. Pharmacology |
| مصطلحات موضوعية: |
dalbavancin, infections, tolerability, Gram-positive infections, antibiotic therapy, Therapeutics. Pharmacology, RM1-950 |
| الوصف: |
Background: Dalbavancin is a long-acting lipoglycopeptide, approved for treatment of skin and skin structure infections. Its PK/PD profile and safety allow for short hospital stays even in the case of difficult-to-treat infections requiring long courses of therapy, e.g., osteomyelitis, cardiovascular, and prosthetic infections. Objectives: We aimed to evaluate the safety and efficacy of dalbavancin in real life settings for both in-label and off-label indications. Methods: retrospective evaluation of all consecutive patients treated with dalbavancin at our site between May 2017 and September 2021. Results: A total of 100 patients treated with dalbavancin and followed up for 6 months after treatment (58% male; median age 63.5 years, median Charlson Comorbidity Index CCI = 2.7, 28% inpatients) were included with the following indications: acute bacterial skin and skin structure infections (22%), bone and prosthetic infections (57%), and cardiovascular infections (19%). Infections were caused by MSSA (30%), MRSA (5%), MR-CoNS (20%), and Streptococcus spp. (8%). In 32 cases, no isolate was obtained. The average number of infusions was 5 (s.d. = 3). Neither ensuing alteration of renal function nor neutropenia or thrombocytopenia were observed during treatment and follow-up. Two self-limiting skin rashes occurred. The overall clinical success rate was 84%—91% for registered and 82% for unregistered indications. The prescription of higher loading doses was the only predictor independently associated with better outcomes in multivariate models (OR: 5.2, 95%CI: 1.5–17.9, p < 0.01). Conclusions: Dalbavancin proved to be effective for skin and skin structure infections, as well as for difficult-to-treat infections in highly comorbid patients. Regarding tolerability, our results support the use of dalbavancin for long-lasting treatments of deep-seated infections. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
2079-6382 |
| Relation: |
https://www.mdpi.com/2079-6382/13/11/1063; https://doaj.org/toc/2079-6382 |
| DOI: |
10.3390/antibiotics13111063 |
| URL الوصول: |
https://doaj.org/article/37381ff87039449b805585bf2bfba4e3 |
| رقم الانضمام: |
edsdoj.37381ff87039449b805585bf2bfba4e3 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder